Skip to main content

Advertisement

Table 2 Participant outcomes

From: Muscle synergies demonstrate only minimal changes after treatment in cerebral palsy

Treatment N Speed GDI N90 tVAF1
   Pre Post Pre Post Pre Post Pre Post
BTA 52 0.32 (0.14) 0.30 (.015) 74.4 (12.2) 74.6 (11.2) 2.87 (0.66) 2.73 (0.69) 0.79 (0.06) 0.80 (0.06)
SDR 38 0.34 (0.12) 0.30 (.011) 73.8 (10.2) 76.6 (13.1) 2.74 (0.50) 2.61 (0.75) 0.80 (0.05) 0.82 (0.05)
SEMLS 57 0.29 (0.11) 0.24 (.013) 66.4 (11.7) 76.8 (12.2) 2.72 (0.70) 2.61 (0.73) 0.80 (0.06) 0.80 (0.06)
TD 31 0.50 (0.09) 93.6 (9.3) 4.19 (0.40) 0.64 (0.03)
  1. NOTE. Values are average (1 SD) or as otherwise indicated
  2. N Number of Participants, Post Post-Treatment, Pre Pre-Treatment,
  3. Speed Non-Dimensional Walking Speed, GDI Gait Deviation Index, N90 Number of Synergies,
  4. tVAF1 Total Variance Accounted for By One Synergy, BTA Botulinum Toxin Type A Injection,
  5. SDR Selective Dorsal Rhizotomy, SEMLS Single Event Multi-Level Orthopaedic Surgery,
  6. TD Typically-Developing Children